IPH.PA vs. STLAP.PA
IPH.PA (Innate Pharma) and STLAP.PA (Stellantis NV) are both stocks. IPH.PA operates in Biotechnology (Healthcare), while STLAP.PA operates in Auto Manufacturers (Consumer Cyclical). Over the past 10 years, IPH.PA returned -18.95%/yr vs -3.19%/yr for STLAP.PA. At a 0.26 correlation, their price movements are largely independent.
Performance
IPH.PA vs. STLAP.PA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IPH.PA achieves a -3.00% return, which is significantly higher than STLAP.PA's -31.69% return. Over the past 10 years, IPH.PA has underperformed STLAP.PA with an annualized return of -18.95%, while STLAP.PA has yielded a comparatively higher -3.19% annualized return.
IPH.PA
- 1D
- 0.91%
- 1M
- 22.56%
- YTD
- -3.00%
- 6M
- -7.06%
- 1Y
- -18.89%
- 3Y*
- -18.21%
- 5Y*
- -12.39%
- 10Y*
- -18.95%
STLAP.PA
- 1D
- 0.96%
- 1M
- -0.85%
- YTD
- -31.69%
- 6M
- -38.33%
- 1Y
- -25.23%
- 3Y*
- -20.37%
- 5Y*
- -12.48%
- 10Y*
- -3.19%
IPH.PA vs. STLAP.PA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
IPH.PA Innate Pharma | -3.00% | -17.08% | -26.26% | -20.36% | -26.03% | 28.48% | -41.91% | -19.84% | 56.53% | -67.49% |
STLAP.PA Stellantis NV | -31.69% | -19.01% | -36.12% | 73.96% | -14.09% | -15.93% | 5.02% | 14.24% | 9.97% | 9.42% |
Correlation
The correlation between IPH.PA and STLAP.PA is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.16 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.14 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.25 |
Correlation (All Time) Calculated using the full available price history since Nov 2, 2006 | 0.26 |
The correlation between IPH.PA and STLAP.PA shifts across timeframes, from 0.14 (3 years) to 0.26 (all time), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IPH.PA vs. STLAP.PA — Risk / Return Rank
IPH.PA
STLAP.PA
IPH.PA vs. STLAP.PA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Innate Pharma (IPH.PA) and Stellantis NV (STLAP.PA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IPH.PA | STLAP.PA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.22 | ||
| Sortino ratioReturn per unit of downside risk | +0.38 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 0.94 | +0.05 |
| Calmar ratioReturn relative to maximum drawdown | -0.41 | -0.55 | +0.14 |
| Martin ratioReturn relative to average drawdown | -0.81 | -1.10 | +0.29 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| IPH.PA | STLAP.PA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.29 | -0.51 | +0.22 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.20 | -0.32 | +0.12 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.33 | -0.08 | -0.25 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.10 | -0.16 | +0.06 |
Drawdowns
IPH.PA vs. STLAP.PA - Drawdown Comparison
The maximum IPH.PA drawdown since its inception was -93.57%, roughly equal to the maximum STLAP.PA drawdown of -93.21%. Use the drawdown chart below to compare losses from any high point for IPH.PA and STLAP.PA.
Loading charts...
Drawdown Indicators
| IPH.PA | STLAP.PA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.57% | -93.21% | -0.36% |
Max Drawdown (1Y)Largest decline over 1 year | -47.59% | -46.94% | -0.65% |
Max Drawdown (3Y)Largest decline over 3 years | -67.61% | -76.32% | +8.71% |
Max Drawdown (5Y)Largest decline over 5 years | -84.91% | -76.32% | -8.59% |
Max Drawdown (10Y)Largest decline over 10 years | -93.22% | -76.32% | -16.90% |
Current DrawdownCurrent decline from peak | -90.54% | -84.66% | -5.88% |
Average DrawdownAverage peak-to-trough decline | -63.73% | -58.46% | -5.27% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.53% | 23.62% | -0.09% |
Volatility
IPH.PA vs. STLAP.PA - Volatility Comparison
Innate Pharma (IPH.PA) has a higher volatility of 38.44% compared to Stellantis NV (STLAP.PA) at 11.07%. This indicates that IPH.PA's price experiences larger fluctuations and is considered to be riskier than STLAP.PA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IPH.PA | STLAP.PA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 38.44% | 11.07% | +27.37% |
Volatility (6M)Calculated over the trailing 6-month period | 49.91% | 41.80% | +8.11% |
Volatility (1Y)Calculated over the trailing 1-year period | 65.73% | 50.55% | +15.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 59.89% | 38.06% | +21.83% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 55.98% | 39.63% | +16.35% |
Dividends
IPH.PA vs. STLAP.PA - Dividend Comparison
Neither IPH.PA nor STLAP.PA has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
IPH.PA Innate Pharma | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
STLAP.PA Stellantis NV | 0.00% | 7.23% | 12.26% | 6.34% | 7.84% | 14.11% |
Financials
IPH.PA vs. STLAP.PA - Financials Comparison
This section allows you to compare key financial metrics between Innate Pharma and Stellantis NV. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
IPH.PA and STLAP.PA have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for IPH.PA and STLAP.PA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer